Papers in ONCOLOGY
Page 3 · newest first
- Minority Enrollment to Clinical Trials: Road to Increased AccessONCOLOGY · 2021
- Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsONCOLOGY · 2021
- Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung CancerONCOLOGY · 2021
- Utility of the 21-Gene Recurrence Score in Node-Positive Breast CancerONCOLOGY · 2021
- Redefining Prostate Cancer CareONCOLOGY · 2021
- Pediatric Locally Advanced Synovial Sarcoma: What Would Be the Best Treatment Option?ONCOLOGY · 2021
- Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional FractionationONCOLOGY · 2021
- WANTED: An “All-Out” National Vaccination ProgramONCOLOGY · 2021
- A Triumph of Science: How Pharmaceutical Innovation Helped Save Our WorldONCOLOGY · 2021
- Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?ONCOLOGY · 2021
- The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer—From “MAYBE” to “MUST BE”ONCOLOGY · 2021
- Addressing Stress and Burnout in Hematology/Oncology PhysiciansONCOLOGY · 2021
- Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate CancerONCOLOGY · 2021
- Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future OutlookONCOLOGY · 2021
- How to Radiologically Assess and Follow Response After Treatment of Hepatocellular CarcinomaONCOLOGY · 2021
- Primary Focal Therapy for Localized Prostate Cancer: A Review of the LiteratureONCOLOGY · 2021
- Prostate Cancer Focal Therapy Has Made Great Strides and the Future Remains BrightONCOLOGY · 2021
- Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell CarcinomaONCOLOGY · 2021
- Molecular Profiling Practices in Pancreatic Adenocarcinoma: Academic vs Community PhysiciansONCOLOGY · 2021
- Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug ConjugatesONCOLOGY · 2021
- Profilin 1 Protein and Its Implications for CancersONCOLOGY · 2021
- FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBCONCOLOGY · 2020
- Supporting Decision-Making on Fertility Preservation Among Adolescent and Young Adult Women With CancerONCOLOGY · 2020
- Promising Therapies Emerging for Recurrent/Metastatic Cervical CancerONCOLOGY · 2020
- Use of Real-World Evidence in Hematology/Oncology Treatment OptimizationONCOLOGY · 2020
- Hitting a New Target in Multiple MyelomaONCOLOGY · 2020
- International Society of Gastrointestinal Oncology Conference AbstractsONCOLOGY · 2020
- Opening Doors: Fertility Preservation for Adolescents and Young Adults FacingGonadotoxic TherapyONCOLOGY · 2020
- Incidence of Metastatic Prostate Cancer On the RiseONCOLOGY · 2020
- FDA Approves Pralsetinib for Treatment of Adults with Metastatic RET Fusion-Positive NSCLCONCOLOGY · 2020
- Screening for Phase 1 Clinical Trials: An Opportunity to Evaluate Psychological States and Reeducate Patients on Prognosis?ONCOLOGY · 2020
- Molecular Profiling in Metastatic Colorectal CancerONCOLOGY · 2020
- Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1ONCOLOGY · 2020
- Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1ONCOLOGY · 2020
- Oncology Clinical Trials During the COVID-19 PandemicONCOLOGY · 2020
- Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus IpilimumabONCOLOGY · 2020
- Forging Ahead in a Time of CrisisONCOLOGY · 2020
- Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute’s Initial ExperienceONCOLOGY · 2020
- Fighting 2 Enemies: Cancer and COVID-19ONCOLOGY · 2020
- A Rational Approach to Managing Prostate Cancer in an Irrational TimeONCOLOGY · 2020